GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (MEX:LABB) » Definitions » 3-Year EPS without NRI Growth Rate

Genomma Lab InternacionalB de CV (MEX:LABB) 3-Year EPS without NRI Growth Rate : -4.70% (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Genomma Lab InternacionalB de CV 3-Year EPS without NRI Growth Rate?

Genomma Lab InternacionalB de CV's EPS without NRI for the three months ended in Mar. 2024 was MXN0.38.

During the past 12 months, Genomma Lab InternacionalB de CV's average EPS without NRI Growth Rate was -16.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was -4.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Genomma Lab InternacionalB de CV was 53.50% per year. The lowest was -4.70% per year. And the median was 17.80% per year.


Competitive Comparison of Genomma Lab InternacionalB de CV's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's 3-Year EPS without NRI Growth Rate falls into.



Genomma Lab InternacionalB de CV 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Genomma Lab InternacionalB de CV  (MEX:LABB) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Genomma Lab InternacionalB de CV 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV (MEX:LABB) Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovalí Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Genomma Lab InternacionalB de CV (MEX:LABB) Headlines

No Headlines